Drug
LU Ag09222
LU Ag09222: highest development phase Phase 2, developed by Lundbeck. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Lundbeck
Trials
| Drug | Phase | Indication |
|---|---|---|
| Lu AG09222 NCT06323928 | Phase 2 | Migraine |
Latest
No recent events.
Follow LU Ag09222 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.